Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05270213 · ClinicalTrials.gov registry record · Phase 1
Evaluation of RBS2418 in Subjects With Advanced, Metastatic Solid Tumors
A Phase 1 study of Advanced Cancer, sponsored by Riboscience.
- Recruiting
- Registry status
- Phase 1
- Development phase
- 164
- Enrollment target
- 14
- Study locations
NCT05270213: Recruiting Phase 1 study of Advanced Cancer, sponsored by Riboscience.
NCT05270213 is a Phase 1 study of Advanced Cancer that is actively recruiting participants, run by Riboscience. The registered enrollment target is 164 participants, below the 245-participant average among 122 other Advanced Cancer trials with a reported enrollment target (33% lower). The trial reports 14 study locations across 11 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05270213, a Phase 1 study of Advanced Cancer, is actively recruiting participants, sponsored by Riboscience.
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 164 participants
- Enrollment target
- 14
- Study locations
Study Summary
RBS2418 (investigational product) is a specific immune modulator, working through ectonucleotide pyrophosphatase/phosphodiesterase I (ENPP1), designed to lead to anti-tumor immunity by increasing endogenous 2'-3'-cyclic guanosine monophosphate-adenosine monophosphate (cGAMP) and adenosine triphosphate (ATP levels) and reducing adenosine production in the tumors. RBS2418 has the potential to be an important therapeutic option for subjects both as monotherapy and in combination with other cancer treatments including monotherapy and in combination with other cancer treatments including immunotherapy or chemotherapy. This study is an open-label, multi-site Phase 1a/1b study of RBS2418, a selective ENPP1 inhibitor, in combination with pembrolizumab or other approved anticancer therapies or as a monotherapy in subjects with advanced unresectable, recurrent or metastatic tumors. The phase 1a (dose escalation phase) has been completed. The Phase 1b expansion phase of the study has been increased in size and scope.
Primary Outcome
When more than 1 DLT occurs in ≤ 6 patients in a dosing cohort, MTD has been exceeded and no more patients are to be treated at that dose level. No DLT observed at the highest dose level in Part A. Part A has been completed.
Conditions Studied
Interventions
- DRUG Pembrolizumab
- DRUG RBS2418
- DRUG Other approved anti-cancer therapy
Study Locations (14)
Arizona
- Honor Health Research Institute - Scottsdale
- University of Arizona - Tucson
California
- Stanford Cancer Institute - Palo Alto
- UCLA Hematology/Oncology - Santa Monica - Santa Monica
Maryland
- Johns Hopkins Sidney Kimmel Comprehensive Cancer Center - Baltimore
- American Oncology Partners of Maryland - Bethesda
Delaware
- Christiana Care Health Services - Newark
Kentucky
- Norton Cancer Institute - Louisville
Louisiana
- Ochsner Clinic Foundation - New Orleans
New York
- Ichan School of Medicine at Mount Sinai - New York
North Carolina
- Carolina BioOncology Institute - Huntersville
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 164 participants |
| Start Date | 2022-07-11 |
| Est. Completion | 2027-12 |
| Phase | Phase 1 |
What NCT05270213 shows while recruiting
NCT05270213 is an interventional study that assigns participants to a tested intervention. The registered 164 participants enrollment target is mid-sized for trials with a published cap, below the 245-participant average among 122 other Advanced Cancer trials with a reported enrollment target (33% lower).
The record links to 1 condition, with Advanced Cancer appearing as the primary indexed condition, and to 3 interventions - of which Pembrolizumab is the first listed.
NCT05270213 lists 14 locations in 11 states (Arizona, California, Maryland).
Frequently Asked Questions
What is clinical trial NCT05270213 about?
NCT05270213 is a clinical study titled "Evaluation of RBS2418 in Subjects With Advanced, Metastatic Solid Tumors". RBS2418 (investigational product) is a specific immune modulator, working through ectonucleotide pyrophosphatase/phosphodiesterase I (ENPP1), designed to lead to anti-tumor immunity by increasing endogenous 2'-3'-cyclic guanosine monophosphate-adenosine monophosphate (cGAMP) and adenosine triphospha...
What is the current status of trial NCT05270213?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 164 participants. The study started on 2022-07-11. Estimated completion is 2027-12.
What conditions does trial NCT05270213 study?
This clinical trial studies the following conditions: Advanced Cancer.
What interventions are being tested in trial NCT05270213?
The interventions under investigation include: Pembrolizumab (DRUG), RBS2418 (DRUG), Other approved anti-cancer therapy (DRUG).
Who is sponsoring clinical trial NCT05270213?
This trial is sponsored by Riboscience, which has 3 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05270213 being conducted?
This trial has 14 study locations across Arizona, California, Delaware, Kentucky, Louisiana. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Advanced Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT05270213's enrollment target sits among peer trials
164 40th of 122 higher than 83 of 122 other Advanced Cancer trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Advanced Cancer trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Phase 1b Trial of BMS-986504 in Combination With Olaparib in Patients With MTAP Loss
RECRUITING · Phase 1
-
A Study of ART0380 for the Treatment of Advanced or Metastatic Solid Tumors
RECRUITING · Phase 1
-
A Study to Evaluate the Safety, Tolerability, Pharmacokinetics (PK), and Antitumor Activity of ALK202 in Participants with Advanced Solid Tumors
RECRUITING · Phase 1
-
A Study in Patients With Advanced Cancers
RECRUITING · Phase 1
-
A Study of MGC026 in Participants With Advanced Solid Tumors
RECRUITING · Phase 1
-
A Study of Oral 7HP349 (Alintegimod) in Combination With Ipilimumab Followed by Nivolumab Monotherapy
RECRUITING · Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT04891289 · 164 participants · Phase 2
Gemcitabine and Oxaliplatin Chemotherapy With or Without a Floxuridine and Dexamethasone Pump in People With Cholangiocarcinoma That Cannot Be Removed With Surgery
- NCT04893226 · 164 participants · NA
Time-Restricted Feeding Intervention in Metabolically-Unhealthy Postmenopausal Women
- NCT05543681 · 164 participants · Phase 2
Clinical Trial on Agitation in Alzheimer's Dementia
- NCT05612594 · 164 participants · Phase 4
Adipose Dysfunction, Imaging, Physiology, and Outcomes With Sodium Glucose Cotransporter 2 Inhibitor (SGLT2i) for Sleep Apnea: The ADIPOSA Study
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI